GL ONC1

Drug Profile

GL ONC1

Alternative Names: GL-ONC1; GLV-1h68

Latest Information Update: 17 Jun 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Genelux Corporation
  • Developer Genelux Corporation; Memorial Sloan-Kettering Cancer Center
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Peritoneal cancer
  • Phase I Head and neck cancer; Malignant pleural effusion; Ovarian cancer; Solid tumours

Most Recent Events

  • 01 May 2016 Phase-I clinical trials in Ovarian cancer (Second-line therapy or greater) in USA (Intraperitoneal) (NCT02759588)
  • 29 Apr 2016 Genelux Corporation plans a phase Ib trial for Ovarian cancer (Second-line therapy or greater) in USA (Intraperitoneal) (NCT02759588)
  • 22 Mar 2016 University of California, San Diego, and Genelux Corporation plan a phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Combination therapy) in USA (NCT02714374)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top